Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome.
As recent clinical and animal studies have indicated, colchicine, with its anti-fibrotic, anti-mitotic and anti-inflammatory activities, has suppressive effects in the pathogenesis of Peyronie's disease. Oral colchicine treatment was initiated in 60 Peyronie's patients during their acute phase (mean duration of disease: 5.7 +/- 4.3 months). Long-term results, based on changes of subjective and objective criteria, were assessed and predictive factors of successful outcome were investigated. After a mean follow-up of 10.7 +/- 4.7 months, the penile deformity improved in 30%, remained unchanged in 48.3% and deteriorated in 21.7%. Pain resolved in 95%. Best results were obtained in those with no risk factor for vascular disease, presenting during the initial 6 months of disease, degree of curvature <30 degrees, no erectile dysfunction by history and positive response to combined injection and stimulation test. In conclusion since tunica albuginea is affected as a whole in Peyronie's disease, systemic oral agents, such as colchicine, may be preferred in the early phase of the disease.
Kadioglu
A
A
Department of Urology, Medical Faculty of Istanbul, University of Istanbul, Turkey. atefeki@anet.net.tr
Tefekli
A
A
Köksal
T
T
Usta
M
M
Erol
H
H
D000328:Adult; D000368:Aged; D003078:Colchicine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain; D010410:Penile Erection; D010411:Penile Induration / Q000188:drug therapy* / Q000473:pathology; D010413:Penis / Q000002:abnormalities; D016896:Treatment Outcome
D003078:Colchicine